Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
- Status
- SUSPENDED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
- Status
- WITHDRAWN
- Phase
- PHASE2
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
- Status
- TERMINATED
- Phase
- PHASE2
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab + Capecitabineļ¼¸Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Early Stage Colon Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Sacituzumab Govitecan In TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Longitudinal Immune-phenotyping of HCC Following MK-3475
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1